Acquired bleeding disorders

Andreas Tiede

doi:10.1111/hae.14995

Acquired bleeding disorders

2024-04-02

2

PRE

AI

DOI：10.1111/hae.14995

Original

Original request for help

Save

Abstract

En 中文

Acquired bleeding disorders can develop in previously healthy people irrespective of age or gender but are particularly common in patients with certain underlying conditions. Here, we review recent advances in the management of acquired haemophilia A (AHA), acquired von Willebrand syndrome (AVWS), and patients with hemostatic abnormalities due to chronic liver disease (CLD). Patients with AHA can now benefit from prophylaxis with emicizumab, a therapeutic antibody that mimics the function of activated coagulation factor VIII. The treatment of AVWS remains challenging in many situations and requires careful consideration of the underlying condition. Haemostatic abnormalities in CLD are often compensated by proportional reduction in pro and anti-haemostatic factors resulting in sustained or even increased thrombin generation. Consequently, bleeding in CLD is rarely caused by haemostatic failure and infusion of plasma or coagulation factor concentrates may not be effective.

Keywords:

coagulation factor deficiencies

Factor VIII

liver disease

von Willebrand factor

Acquired bleeding disorders

Abstract

Journal

Organization